Recent Therapeutic Advances and Updates in the Management of MSI-H Colorectal Cancer: A Closer Look at the Evolving Role of Immunotherapy
is a two-part webinar series

A continuing medical education activity sponsored by NAMCP and AAMCN

This webinar series will provide critical updates on the advances in the management of Colorectal Cancer

These are archives of live webinars held between February 24, 2021 to February 26, 2021
If you participated in any of the live webinars, you are not eligible to claim credit from the archive of that webinar.

By clicking on each of the titles, you will be able to participate in each part.
It is not required that you participate in all three or in order.

These activities are valid from March 1, 2021 to March 1, 2023


This series is supported by an educational grant from
Merck Sharp & Dohme Corp.


 
Audience: This activity is intended for healthcare professionals practicing in managed care environments.

Instructions for CME/NCPD: Complete the pre-test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. You will be asked to enter your name and email address on the pre-test, evaluation and post-test. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate.

Description:
Colorectal cancer (CRC) is the development of cancer from the colon or rectum, due to the abnormal growth of cells that have the ability to invade or spread to other parts of the body. Excluding skin cancers, CRC is the third most common cancer diagnosed in both men and women in the United States. In 2021, it is expected that there will be 149,500 new cases of colorectal cancer and 52,980 deaths. When discovered early, CRC is highly treatable. However, when the disease has spread, treatment becomes much more difficult. Fortunately, immunotherapy options have become available for patients with metastatic CRC, particular in MSI-High disease, giving clinicians and managed care professionals more options in managing this patient population.


Comparative Effectiveness and Payer-Provider Coordination in MSI-H Colorectal Cancer: What Managed Care Needs to Know About Recent Advances in Immunotherapy

  1. Identify current unmet economic needs in the management of MSI-H colorectal cancer and evidence-based recommendations for the care of patients with these tumors
  2. Review the role of immune checkpoint inhibitors in the management of MSI-H colorectal cancer in the first-line setting
  3. Describe approaches currently utilized by third party payers to manage costs associated with the care of patients with MSI-H colorectal cancer
  4. Discuss the managed care considerations of immunotherapy by exploring where these agents fit in the evolving MSI-H colorectal cancer management paradigm
       Physician, Nursing and CMCN credits valid to March 1, 2023

Recent Therapeutic Advances and Updates in the Management of MSI-H Colorectal Cancer: A Closer Look at the Evolving Role of Immunotherapy

  1. Identify current unmet clinical and economic needs in the management of MSI-H colorectal cancer and evidence-based recommendations for the care of patients with these tumors
  2. Use results of MSI/dMMR testing to determine appropriate management of advanced CRC
  3. Examine recent clinical data on the safety and efficacy of immune checkpoint inhibitors in the first-line management of MSI-H colorectal cancer in the first line setting
  4. Examine evidence-based strategies to monitor for, recognize, and effectively manage potential irAEs associated with immune checkpoint inhibition in MSI-H colorectal cancer
    Identify patients with MSI-H colorectal cancer who would potentially benefit from immunotherapies, in first-line settings or beyond
       Physician, Nursing and CMCN credits valid to March 1, 2023